Hands down to PDAB. Keeping prior authorizations from getting lost during a plan change seems like a pretty practical way to protect continuity of care.
September 18, 2026 at 5:16 AM
Hands down to PDAB. Keeping prior authorizations from getting lost during a plan change seems like a pretty practical way to protect continuity of care.
Oregon is set to receive nearly $200 million to transform rural health, but questions are being raised about the accuracy of pharmacy access maps that could mislead communities about their local resources.
Get the details!
#OR #RuralHealth #HealthcareAccess
Get the details!
#OR #RuralHealth #HealthcareAccess
Oregon Office of Rural Health briefs PDAB on rural pharmacy access, RHTP funds and mapping limits
The director of Oregon’s Office of Rural Health told the board the state received a $197 million Rural Health Transformation Program award and described challenges getting funds moving to communities. Board members asked for clearer maps of patient‑facing pharmacies after staff acknowledged the current map may overcount licensed dispensing points.
citizenportal.ai
September 17, 2026 at 6:47 PM
Oregon is set to receive nearly $200 million to transform rural health, but questions are being raised about the accuracy of pharmacy access maps that could mislead communities about their local resources.
Get the details!
#OR #RuralHealth #HealthcareAccess
Get the details!
#OR #RuralHealth #HealthcareAccess
The debate is heating up as board members consider whether to eliminate the orphan-drug exemption entirely, sparking fierce discussions about drug affordability for rare-disease patients.
Get the details!
#OR #RareDiseaseAwareness #HealthcareAccess #PharmaceuticalRegulation
Get the details!
#OR #RareDiseaseAwareness #HealthcareAccess #PharmaceuticalRegulation
PDAB asks staff to draft two options on orphan‑drug exemption — carve‑out or full removal
Board members split over whether to remove the orphan‑drug exemption entirely or refine it so only 'orphan‑only' drugs remain exempt; staff will draft language for both options for next meeting.
citizenportal.ai
September 17, 2026 at 6:45 PM
The debate is heating up as board members consider whether to eliminate the orphan-drug exemption entirely, sparking fierce discussions about drug affordability for rare-disease patients.
Get the details!
#OR #RareDiseaseAwareness #HealthcareAccess #PharmaceuticalRegulation
Get the details!
#OR #RareDiseaseAwareness #HealthcareAccess #PharmaceuticalRegulation
Oregon is taking a bold step to protect patients by drafting new legislation that preserves essential prior authorizations during health plan transitions!
Learn more here
#OR #HealthcareAccess #PatientProtection
Learn more here
#OR #HealthcareAccess #PatientProtection
Oregon PDAB asks staff to draft continuity‑of‑care recommendation to ease prior‑auth transitions
The Oregon Prescription Drug Affordability Board directed staff to draft recommendation language to preserve prior authorizations and step‑therapy approvals during plan transitions — board members favored a 90‑day transition and asked for mechanisms to transfer authorizations and notify pharmacies.
citizenportal.ai
September 17, 2026 at 6:44 PM
Oregon is taking a bold step to protect patients by drafting new legislation that preserves essential prior authorizations during health plan transitions!
Learn more here
#OR #HealthcareAccess #PatientProtection
Learn more here
#OR #HealthcareAccess #PatientProtection
The board's recent meeting revealed key drug decisions for the 2026 affordability review, with several major players like Keytruda and Skyrizi poised for further scrutiny before the crucial November vote.
Get the details!
#OR #PharmaceuticalTransparency #PublicCommentary
Get the details!
#OR #PharmaceuticalTransparency #PublicCommentary
PDAB triages 2026 drug reviews: several pushed to November vote; Keytruda, Skyrizi and a few biologics get extra scrutiny
Staff presented packet summaries for 2026 drug reviews. The board decided not to reopen full discussions on several drugs (Humulin RU‑500, Jardiance, semaglutide/tirzepatide GLPs, Xeljanz) before November; Keytruda, Skyrizi, Tremfya and Ocrevus were flagged for additional staff clarifications and context for the final vote.
citizenportal.ai
September 17, 2026 at 6:43 PM
The board's recent meeting revealed key drug decisions for the 2026 affordability review, with several major players like Keytruda and Skyrizi poised for further scrutiny before the crucial November vote.
Get the details!
#OR #PharmaceuticalTransparency #PublicCommentary
Get the details!
#OR #PharmaceuticalTransparency #PublicCommentary
Oregon's board is taking a bold step towards transparency in pharmacy benefit management, aiming to uncover where discounts and fees are really going.
Click to read more!
#OR #HealthcarePolicy
Click to read more!
#OR #HealthcarePolicy
After wide debate, PDAB asks staff to refine PBM memo and start with transparency and audit authorities
The board asked staff to prioritize transparency and audit rights in its pharmacy benefit manager policy memo and to cross‑reference the Oregon Secretary of State report; staff will refine language and identify prior PDAB recommendations to build on.
citizenportal.ai
September 17, 2026 at 6:42 PM
Oregon's board is taking a bold step towards transparency in pharmacy benefit management, aiming to uncover where discounts and fees are really going.
Click to read more!
#OR #HealthcarePolicy
Click to read more!
#OR #HealthcarePolicy
The way I see it, people completely confuse state reimbursement caps with actual wholesale discounts. A PDAB board capping what the state pays doesn't force pharma to lower their launch price PBM bulk leverage is what actually squeezes net costs down for plan sponsors.
September 15, 2026 at 5:46 PM
The way I see it, people completely confuse state reimbursement caps with actual wholesale discounts. A PDAB board capping what the state pays doesn't force pharma to lower their launch price PBM bulk leverage is what actually squeezes net costs down for plan sponsors.
A PDAB caps what the state pays. That is not the manufacturer list and it is not a reason to fire the PBM a plan already hired. Hold the drugmaker. The board is not a cheaper pickup.
x.com/koje72/statu...
x.com/koje72/statu...
KJ (@koje72) on X
RT @JocelynBenson: No one should have to choose between lifesaving medicine and their life’s savings.
I will create a Prescription Drug Af…
x.com
September 15, 2026 at 2:38 AM
A PDAB caps what the state pays. That is not the manufacturer list and it is not a reason to fire the PBM a plan already hired. Hold the drugmaker. The board is not a cheaper pickup.
x.com/koje72/statu...
x.com/koje72/statu...
Por que a GEN Z está olhando para trás?
YouTube video by Alberto Cafeeiro
www.youtube.com
September 6, 2026 at 11:30 PM
Maryland’s PDAB still has no commercial OOP cut and an audit says it left $1.4M in assessments sitting uncollected. If the board cannot run its own fee file, it is not the thing lowering the launch price for a pool of lives.
thebaynet.com/state-audit-...
thebaynet.com/state-audit-...
State Audit Finds $1.4 Million In Unpaid Fees At Maryland Prescription Drug Affordability Board - The BayNet
ANNAPOLIS, Md. — Maryland’s Prescription Drug Affordability Board failed to adequately collect and account for annual fees used to fund its operations, leaving approximately $1.4 million outstanding a...
thebaynet.com
September 4, 2026 at 4:37 PM
Maryland’s PDAB still has no commercial OOP cut and an audit says it left $1.4M in assessments sitting uncollected. If the board cannot run its own fee file, it is not the thing lowering the launch price for a pool of lives.
thebaynet.com/state-audit-...
thebaynet.com/state-audit-...
The Maryland Prescription Drug Affordability Board (PDAB) is available as a state resource to help connect residents with staff who can find available programs and resources.
For more information visit: pdab.maryland.gov/cost-reviews...
For more information visit: pdab.maryland.gov/cost-reviews...
August 27, 2026 at 7:42 PM
The Maryland Prescription Drug Affordability Board (PDAB) is available as a state resource to help connect residents with staff who can find available programs and resources.
For more information visit: pdab.maryland.gov/cost-reviews...
For more information visit: pdab.maryland.gov/cost-reviews...
so the work was not funded under Governor Hogan, but the Moore administration is fully on board, and PDAB has finally approved upper limits on a few drugs, first applied to only what state and local governments pay, and soon extends to all of us.
(From the @aacoexec.bsky.social weekly letter)
(From the @aacoexec.bsky.social weekly letter)
August 10, 2026 at 6:54 PM
so the work was not funded under Governor Hogan, but the Moore administration is fully on board, and PDAB has finally approved upper limits on a few drugs, first applied to only what state and local governments pay, and soon extends to all of us.
(From the @aacoexec.bsky.social weekly letter)
(From the @aacoexec.bsky.social weekly letter)
This is why I support @govwesmoore.bsky.social
"...the establishment of the Prescription Drug Affordability Board (PDAB), a state chartered group that reviews what the drug companies get paid for their drugs and puts limits when they are overpriced. The law was not popular with drug companies,
"...the establishment of the Prescription Drug Affordability Board (PDAB), a state chartered group that reviews what the drug companies get paid for their drugs and puts limits when they are overpriced. The law was not popular with drug companies,
August 10, 2026 at 6:54 PM
This is why I support @govwesmoore.bsky.social
"...the establishment of the Prescription Drug Affordability Board (PDAB), a state chartered group that reviews what the drug companies get paid for their drugs and puts limits when they are overpriced. The law was not popular with drug companies,
"...the establishment of the Prescription Drug Affordability Board (PDAB), a state chartered group that reviews what the drug companies get paid for their drugs and puts limits when they are overpriced. The law was not popular with drug companies,
Big Pharma is trying to stop Colorado from paying less for life-saving medications. Centennial State Prosperity was excited to see the state’s PDAB appeal a preliminary injunction that would prevent the state from limiting the cost of Enbrel, an expensive Rheumatoid Arthritis medication.
August 5, 2026 at 10:54 PM
Big Pharma is trying to stop Colorado from paying less for life-saving medications. Centennial State Prosperity was excited to see the state’s PDAB appeal a preliminary injunction that would prevent the state from limiting the cost of Enbrel, an expensive Rheumatoid Arthritis medication.
via Partnership For Safe Medicines - How much have PDABs spent to date? $28mm over 5 years, with not a single patient ever seeing the financial benefits of an Upper Payment Limit: https://www.safemedicines.org/wp-content/uploads/2026/06/2026-update-PDAB-infographic-numbers-v2-1.pdf
August 5, 2026 at 1:35 PM
via Partnership For Safe Medicines - How much have PDABs spent to date? $28mm over 5 years, with not a single patient ever seeing the financial benefits of an Upper Payment Limit: https://www.safemedicines.org/wp-content/uploads/2026/06/2026-update-PDAB-infographic-numbers-v2-1.pdf
In Colorado and Maryland, Prescription Drug Affordability Boards #PDABs treat public engagement as an inconvenient formality rather than a crucial component of sound healthcare policy development.
Transparency matters. Public voices must be heard on matters that directly affect patients' health.
Transparency matters. Public voices must be heard on matters that directly affect patients' health.
PDAB Chicanery - How Drug Affordability Boards Are Undermining Public Engagement
Analysis of state Prescription Drug Affordability Board procedures and lack of transparency in drug pricing decision-making.
www.tiicann.org
July 27, 2026 at 11:29 PM
In Colorado and Maryland, Prescription Drug Affordability Boards #PDABs treat public engagement as an inconvenient formality rather than a crucial component of sound healthcare policy development.
Transparency matters. Public voices must be heard on matters that directly affect patients' health.
Transparency matters. Public voices must be heard on matters that directly affect patients' health.
via @SafeMedicines - Virginia's governor vetoed the state's highly anticipated PDAB legislation
www.youtube.com/watch?v=QWhS...
www.youtube.com/watch?v=QWhS...
Virginia's governor vetoed the state's highly anticipated PDAB legislation.
YouTube video by SafeMedicines
www.youtube.com
July 13, 2026 at 1:35 PM
via @SafeMedicines - Virginia's governor vetoed the state's highly anticipated PDAB legislation
www.youtube.com/watch?v=QWhS...
www.youtube.com/watch?v=QWhS...
"The PDAB set the price cap, which was scheduled to go into effect in 2027, at around $31,000 per year. The pharma company Amgen, which manufactures Enbrel, sued, arguing that the cap undermines federal patent law and would cause the company economic harm."
coloradosun.com/2026/07/02/p...
coloradosun.com/2026/07/02/p...
Judge temporarily blocks Colorado’s first-in-the-nation price cap on a prescription drug
A federal judge has temporarily blocked a price cap set by Colorado's Prescription Drug Affordability Board on Amgen's blockbuster drug Enbrel.
coloradosun.com
July 2, 2026 at 2:41 PM
"The PDAB set the price cap, which was scheduled to go into effect in 2027, at around $31,000 per year. The pharma company Amgen, which manufactures Enbrel, sued, arguing that the cap undermines federal patent law and would cause the company economic harm."
coloradosun.com/2026/07/02/p...
coloradosun.com/2026/07/02/p...
A Drug Affordability Board won't lower what Virginians pay at the counter, but could leave 200+ infusion centers facing reimbursement that doesn't cover the cost of care. Brian Nyquist on why Gov. Spanberger was right to veto PDAB legislation in @RTDNEWS: bit.ly/4w3YXBA
A necessary veto leaves the bigger question: How wlll drug costs fall? | Guest column
Governor Abigail Spanberger's veto of Virginia's proposed Prescription Drug Affordability Board was a necessary, evidence‑based decision that protects patients from policies that threaten access to infusion therapies, destabilize the pharmaceutical
bit.ly
June 22, 2026 at 7:00 PM
A Drug Affordability Board won't lower what Virginians pay at the counter, but could leave 200+ infusion centers facing reimbursement that doesn't cover the cost of care. Brian Nyquist on why Gov. Spanberger was right to veto PDAB legislation in @RTDNEWS: bit.ly/4w3YXBA
Maryland's PDAB-approved Ozempic price cap limits what government insurers pay, but does not reduce patient out-of-pocket costs. Industry and patient groups warn it could make the drug harder to get. Read more: https://tinyurl.com/ysrssvpf #ProtectPatients #Maryland
Maryland caps Ozempic price for government insurers beginning in 2027
Schmitt said dropping coverage for weight loss does financially hurt employees who do not have better alternatives. “Many employees turn to GLP-1 drugs after other weight loss treatments have proven ineffective.”
tinyurl.com
May 29, 2026 at 2:01 PM
Maryland's PDAB-approved Ozempic price cap limits what government insurers pay, but does not reduce patient out-of-pocket costs. Industry and patient groups warn it could make the drug harder to get. Read more: https://tinyurl.com/ysrssvpf #ProtectPatients #Maryland
Honored to testify at the Oregon Prescription Drug Affordability Board yesterday on behalf of @voicesofhealthcare.org representing 3,567 Oregonians.
It's time for the Oregon PDAB to take action to make high-cost drugs more affordable for all Oregonians.
It's time for the Oregon PDAB to take action to make high-cost drugs more affordable for all Oregonians.
Oregon Prescription Drug Affordability Board Meeting of May 20, 2026
YouTube video by Oregon Division of Financial Regulation
www.youtube.com
May 21, 2026 at 11:08 PM
Honored to testify at the Oregon Prescription Drug Affordability Board yesterday on behalf of @voicesofhealthcare.org representing 3,567 Oregonians.
It's time for the Oregon PDAB to take action to make high-cost drugs more affordable for all Oregonians.
It's time for the Oregon PDAB to take action to make high-cost drugs more affordable for all Oregonians.
ICER #WeeklyView: ISA webinar, a jump in high-deductible ACA plans, & Maryland PDAB on obesity Rx conta.cc/4fxpxxS
ICER Weekly View: ISA webinar, a jump in high-deductible ACA plans, & Maryland PDAB on obesity Rx
Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Weekly View May 21, 2026 From the desk of Priya Ranade Good morning,
conta.cc
May 21, 2026 at 1:27 PM
ICER #WeeklyView: ISA webinar, a jump in high-deductible ACA plans, & Maryland PDAB on obesity Rx conta.cc/4fxpxxS
Rx price cap bill passes committee
Rx price cap bill passes committee - Capitol City Now
Opponents say PDAB proposal lacks organization.
capitolcitynow.com
May 21, 2026 at 12:02 PM
Rx price cap bill passes committee
Rx price cap bill passes committee
Rx price cap bill passes committee - Capitol City Now
Opponents say PDAB proposal lacks organization.
capitolcitynow.com
May 21, 2026 at 11:57 AM
Rx price cap bill passes committee
Rx price cap bill passes committee
Rx price cap bill passes committee - Capitol City Now
Opponents say PDAB proposal lacks organization.
capitolcitynow.com
May 21, 2026 at 11:55 AM
Rx price cap bill passes committee